Anirudha Dasgupta
Expertise in
10
conditions

Dr. Anirudha Dasgupta

Oncology | Hematology
506 Medical Center Blvd, Ste 100, 
Conroe, TX 
Accepting New Patients
Expertise in
10
conditions
506 Medical Center Blvd, Ste 100, 
Conroe, TX 

Overview

Anirudha Dasgupta, MD, earned his medical degree from the University of Delhi’s Maulana Azad Medical College in India. He went on to complete residencies at All India Institute of Medical Sciences in New Delhi, and at Lincoln Medical & Mental Health Center, where he served as chief resident in internal medicine. The hospital is now named NYC Health + Hospitals/Lincoln and is located in The Bronx in New York City. He then completed a fellowship with Harvard Medical School at Massachusetts General Hospital in Boston. Board certified in medical oncology and hematology, Dr. Dasgupta treats patients with all types of cancer and blood disorders. He is a Fellow of the American College of Physicians (ACP) and is a member of the American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH). Throughout his education and career, Dr. Dasgupta has been honored with numerous recognitions. The Government of India’s National Council of Educational Research & Training awarded him the National Science Talent Search Scholarship for 13 consecutive years. At the University of Delhi, he was honored the Gold Medal in Anatomy, the Gold Medal in Surgery and the Prize for Preventive and Social Medicine. The American Association of Cancer Research awarded Dr. Dasgupta with a scholarship, which allowed him to attend a Molecular Biology Workshop. Dr. Dasgupta was born in India and speaks Bengali, Hindi and Urdu.

Dr. Dasgupta is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Familial Mixed Cryoglobulinemia, Cryoglobulinemia, Lung Cancer, and Pleuropulmonary Blastoma.

He is actively involved in clinical research, participating in 7 clinical trials. Dr. Dasgupta is currently accepting new patients.

Specialties

Oncology
Hematology

Licenses

Internal Medicine in TX

Fellowships

Massachusetts General Hospital 1996

Hospital Affiliations

Memorial Hermann Hospital System
Houston Methodist The Woodlands Hospital
Huntsville Memorial Hospital
Hca Houston Healthcare Conroe
Hca Houston Healthcare Kingwood
Memorial Hermann Cypress Hospital
Memorial Hermann Northeast Hospital
Memorial Hermann The Woodlands Hospital

Languages Spoken

English
Bengali
Hindi
Urdu

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

506 Medical Center Blvd, Ste 100, Conroe, TX 77304
Other Locations
22710 Professional Dr, Ste 100, Kingwood, TX 77339

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: June 15, 2026
Intervention Type: Drug
Study Drugs: Zimberelimab, Domvanalimab, Etrumadenant
Study Phase: Phase 2
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Carboplatin, Etoposide, Atezolizumab
Study Phase: Phase 2
A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors
A Randomized Phase III Trial of OSE2101 Compared With Chemotherapy (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small Cell Lung Cancer With Progressive Disease After Immune Checkpoint Inhibitors
Enrollment Status: Terminated
Publish Date: February 02, 2024
Intervention Type: Drug, Biological
Study Drugs: OSE2101, Docetaxel, Pemetrexed
Study Phase: Phase 3
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole, Goserelin, Leuprolide
Study Phase: Phase 3
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
Enrollment Status: Terminated
Publish Date: January 20, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Enrollment Status: Terminated
Publish Date: September 11, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
A Phase 1 Trial of CV301 in Combination With Anti- PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer
A Phase 1 Trial of CV301 in Combination With Anti- PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: February 27, 2020
Intervention Type: Biological
Study Phase: Phase 1
View 6 Less Clinical Trials
Similar Doctors
Expertise in
27
conditions
Dr. William G. Wierda
Hematology | Oncology
Expertise in
27
conditions
Dr. William G. Wierda
Hematology | Oncology
Referral may be required

University Of Texas MD Anderson Cancer Center

1515 Holcombe Blvd Unit 428, 
Houston, TX 
 (40.1 miles away)
713-792-7040
Languages Spoken:
English
See accepted insurances

William Wierda is a Hematologist and an Oncologist practicing medicine in Houston, Texas. Dr. Wierda is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
22
conditions
Dr. Murali M. Chintagumpala
Hematology | Oncology
Expertise in
22
conditions
Dr. Murali M. Chintagumpala
Hematology | Oncology
Referral may be required

Baylor College Of Medicine

6701 Fannin St, 
Houston, TX 
 (40.0 miles away)
832-822-4242
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Murali Chintagumpala is a Hematologist and an Oncologist practicing medicine in Houston, Texas. Dr. Chintagumpala is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Gliomatosis Cerebri, Brain Tumor, Posterior Fossa Tumor, and Nephrectomy. Dr. Chintagumpala is currently accepting new patients.

Expertise in
12
conditions
Dr. Carl E. Allen
Hematology | Oncology
Expertise in
12
conditions
Dr. Carl E. Allen
Hematology | Oncology
Referral may be required

Office

1102 Bates Ave Ste 750, 
Houston, TX 
 (40.1 miles away)
832-824-4312
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Carl Allen is a Hematologist and an Oncologist practicing medicine in Houston, Texas. Dr. Allen is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Langerhans Cell Histiocytosis, Reticulohistiocytoma, Histiocytosis, Hemophagocytic Lymphohistiocytosis, and Bone Marrow Transplant. Dr. Allen is currently accepting new patients.

Frequently Asked Questions about Dr. Anirudha Dasgupta

How do I make an appointment with Dr. Anirudha Dasgupta?

You can book an appointment with Dr. Anirudha Dasgupta by calling their office at 281-569-2130. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Anirudha Dasgupta a top-rated expert for Familial Mixed Cryoglobulinemia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Anirudha Dasgupta is classified as an Advanced expert for Familial Mixed Cryoglobulinemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Anirudha Dasgupta specialize in?

While Dr. Anirudha Dasgupta is a Oncology, they have specific expertise in Familial Mixed Cryoglobulinemia, Cryoglobulinemia, and Lung Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Anirudha Dasgupta accept my insurance?

Dr. Anirudha Dasgupta accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 281-569-2130 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dasgupta's expertise for a condition
ConditionClose
      View All 10 Advanced Conditions
      View All 79 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile